Hans Lee, MD, Sarah Cannon Research Institute, explains new IMS/IMWG cure criteria for myeloma and the meaning of durable CAR-T responses in these patients.
Hans C. Lee, MD
Advertisement
Articles by Hans C. Lee, MD
Hans Lee, MD, discusses the importance of BCMA-targeted therapy and the differences between CAR T and bispecific antibody therapy in multiple myeloma.
ASH 2025 highlighted groundbreaking advancements in multiple myeloma treatment, focusing on bispecific T-cell antibodies for improved patient outcomes.
Hans C. Lee, MD, discusses the toxicity seen with the BCMA/CD3 bispecific antibody linvoseltamab for patients with relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Dr Hans Lee on the Game-Changing Myeloma Research From ASH 2025December 15th 2025
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
2
Hormone Receptor Status, HER2DX Score Predict Response to Neoadjuvant THP
3
Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia
4
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
5